Zen Technologies stock plunges 10% on Q3 results, despite buy calls, as company faces growth concerns and order delays.

When COVID-19 vaccines rolled out, public health officials largely followed a simple logic: protect the most vulnerable first ...

First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025New 12-month ...

First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025New 12-month data on the first three adult OPGx-LCA5 patients to be pr ...